RESUMEN
Heparan sulfate proteoglycans (HSPGs) participate in numerous normal and pathophysiological cellular functions. HSPGs are crucial components of the extracellular matrix (ECM) binding signalling molecules such as fibroblast growth factors (FGF) and Wnts to mediate various cellular processes including cell proliferation, migration, and cancer invasion. The syndecans (SDCs1-4) are a major family of four HSPGs, implicated in the development of breast carcinomas. This study examined syndecan-1 (SDC1) and syndecan-4 (SDC4; SDC1/4) in breast cancer (BC) in vitro cell models and their role in tumorigenesis. Gene expression of HSPG core proteins, biosynthesis and modification enzymes along with Wnt/FGF morphogen pathway components were examined following inhibition of SDC1 and SDC4 via small interfering RNA (siRNA), and enhancement of HSPGs via addition of heparin and FGF. siRNAs knockdowns (KDs) were performed in the MCF-7 (lowly invasive and poorly metastatic) and the MDA-MB-231 (highly invasive and metastatic) human BC cell lines. Significantly decreased gene expression of SDC1 and SDC4 was observed in both cell lines following KD. Additionally, via gene expression analysis, downregulation of SDC1/4 decreased the biosynthesis of heparan sulfate modification enzymes and reduced expression of Wnt signalling molecules. Following the enhancement/inhibition of HSPGs via heparin/siRNA treatment, heparin increased the migratory characteristics of MCF-7 cells while KD of SDC1 increased cell migration in both MCF-7 and MDA-MB-231 cells when compared to scramble negative control conditions. Our findings suggest that a niche-specific function exists for SDC1/4 in the BC microenvironment, mediating Wnt signalling cascades and potentially regulating migration of BC cells.
Asunto(s)
Neoplasias de la Mama , Sindecano-1 , Neoplasias de la Mama/metabolismo , Movimiento Celular , Femenino , Heparina , Humanos , ARN Interferente Pequeño/genética , Sindecano-1/genética , Sindecano-4 , Microambiente Tumoral , Vía de Señalización WntRESUMEN
New drug leads for the treatment of inflammation are urgently needed. Marine molluscs are widely used as traditional medicines for the treatment of inflammation. Here we report the positive effects of a hypobranchial gland (HBG) extract and the dominant bioactive compound 6-bromoisatin from the Muricidae mollusc Dicathais orbita, for reducing lipopolysaccharide (LPS) induced acute lung inflammation in a mouse model. Both 6-bromoisatin and the HBG extract suppressed the inflammatory response in mice that were pre-treated by oral gavage at 48, 24 and 1 h prior to LPS infusion. The inflammatory antagonists were tested at concentrations of 0.5 mg/g and 0.1 mg/g HBG extract and 0.1 mg/g and 0.05 mg/g 6-bromoisatin in carrier oil and all treatments reduced inflammation as indicated by a significant suppression of inflammatory markers present in bronchoalveolar lavage fluid (BALF), in comparison to LPS induced positive control mice administered the carrier oil alone (p < 0.0001). Tumour necrosis factor-alpha (TNFα) and interleukin-1 beta (IL-1ß) levels, in addition to total protein concentration were all significantly reduced in BALF from mice treated with the extract or 6-bromoisatin. Furthermore, all treatment groups showed significant reductions in neutrophil sequestration and preservation of the lung tissue architecture compared to the positive control (p < 0.0001). The combined results from this study and our previous in vitro studies indicate that 6-bromoisatin in the HGB extracts inhibit the activation of inflammatory signalling pathway. The results from this study further confirm that the HBG extract from Muricidae molluscs and 6-bromoisatin are bioavailable and effective in vivo, thus have potential for development as natural therapeutic agents for inflammation.